Dystrophin is a large molecular weight component of the muscle and nerve cell cytoskeleton. Disruption of normal function leads to the genetic disorders Duchenne and Becker muscular dystrophy. Deletion mutations are the most common means to disrupt function but other mutations are known to exist. The proposed characterization of these other mutations will greatly increase the accuracy of diagnosis for at risk individuals and should shed additional light on how normal function can be affected. Dystrophin has been shown to be a member of a family of related proteins with overlapping yet discreet functions. Some of these related proteins may partially compensate for absent dystrophin and hence represent potential candidates for therapeutic intervention to strengthen the compensatory ability. These related proteins are themselves prime candidates to be disrupted in other neuromuscular diseases which, like Duchenne and Becker dystrophy, are slowly progressive. New members of the family will be cloned, mapped to chromosomal locations, and tested for disruption in candidate neuromuscular diseases. Functional analysis of these proteins should shed light on their role in the membrane cytoskeleton and how this role is altered in disease. This should result not only in the identification of other disease causing genes, but also proteins with the potential to mitigate the absence of dystrophin in Duchenne dystrophy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS023740-08
Application #
3407560
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1986-07-01
Project End
1998-06-30
Budget Start
1993-07-01
Budget End
1994-06-30
Support Year
8
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Children's Hospital Boston
Department
Type
DUNS #
076593722
City
Boston
State
MA
Country
United States
Zip Code
02115
Bonnemann, C G; Wong, J; Jones, K J et al. (2002) Primary gamma-sarcoglycanopathy (LGMD 2C): broadening of the mutational spectrum guided by the immunohistochemical profile. Neuromuscul Disord 12:273-80
Peters, M F; Sadoulet-Puccio, H M; Grady, M R et al. (1998) Differential membrane localization and intermolecular associations of alpha-dystrobrevin isoforms in skeletal muscle. J Cell Biol 142:1269-78
Scharf, J M; Endrizzi, M G; Wetter, A et al. (1998) Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics. Nat Genet 20:83-6
Chan, Y; Tong, H Q; Beggs, A H et al. (1998) Human skeletal muscle-specific alpha-actinin-2 and -3 isoforms form homodimers and heterodimers in vitro and in vivo. Biochem Biophys Res Commun 248:134-9
Bonnemann, C G; Wong, J; Ben Hamida, C et al. (1998) LGMD 2E in Tunisia is caused by a homozygous missense mutation in beta-sarcoglycan exon 3. Neuromuscul Disord 8:193-7
Peters, M F; O'Brien, K F; Sadoulet-Puccio, H M et al. (1997) beta-dystrobrevin, a new member of the dystrophin family. Identification, cloning, and protein associations. J Biol Chem 272:31561-9
Carter, T A; Bonnemann, C G; Wang, C H et al. (1997) A multicopy transcription-repair gene, BTF2p44, maps to the SMA region and demonstrates SMA associated deletions. Hum Mol Genet 6:229-36
Gussoni, E; Blau, H M; Kunkel, L M (1997) The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 3:970-7
Sadoulet-Puccio, H M; Feener, C A; Schaid, D J et al. (1997) The genomic organization of human dystrobrevin. Neurogenetics 1:37-42
Sadoulet-Puccio, H M; Rajala, M; Kunkel, L M (1997) Dystrobrevin and dystrophin: an interaction through coiled-coil motifs. Proc Natl Acad Sci U S A 94:12413-8

Showing the most recent 10 out of 61 publications